{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:49:56Z","timestamp":1776826196240,"version":"3.51.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41397-026-00404-6","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:45:17Z","timestamp":1775195117000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of folylpolyglutamate synthase polymorphisms with methotrexate response and toxicity in rheumatoid arthritis: a meta-analysis"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4213-1909","authenticated-orcid":false,"given":"Young Ho","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwan Gyu","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"404_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4078\/jrd.2024.0072","volume":"32","author":"YH Lee","year":"2025","unstructured":"Lee YH, Jun J-B. Assessment of disease activity and quality of life of Korean patients with rheumatoid arthritis. J Rheum Dis. 2025;32:3\u20137.","journal-title":"J Rheum Dis"},{"key":"404_CR2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.4078\/jrd.2024.0151","volume":"32","author":"B Ghang","year":"2025","unstructured":"Ghang B, Park JK, Ju JH, Han S. Current state and future directions of basic research in rheumatoid arthritis. J Rheum Dis. 2025;32:166\u201381.","journal-title":"J Rheum Dis"},{"key":"404_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jbspin.2018.07.004","volume":"86","author":"B Friedman","year":"2019","unstructured":"Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019;86:301\u20137.","journal-title":"Joint Bone Spine"},{"key":"404_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4078\/jrd.2024.0073","volume":"32","author":"I-W Baek","year":"2025","unstructured":"Baek I-W, Park K-S, Kim K-J. An erythrocyte macrocytosis by methotrexate is associated with early initiation of biologic or targeted synthetic agents in patients with rheumatoid arthritis. J Rheum Dis. 2025;32:30\u20137.","journal-title":"J Rheum Dis"},{"key":"404_CR5","doi-asserted-by":"crossref","unstructured":"Sundaresan J, Verstoep LJ, Jansen G, de Jonge R, de Rotte MC, Bulatovi\u0107-\u0106alasan M. Personalized methotrexate treatment in immune-mediated inflammatory diseases: a narrative review. Journal of Laboratory and Precision Medicine. 2025;10:13.","DOI":"10.21037\/jlpm-25-7"},{"key":"404_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.ctrv.2014.05.003","volume":"40","author":"S Liu","year":"2014","unstructured":"Liu S, Kurzrock R. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer Treat Rev. 2014;40:883\u201391.","journal-title":"Cancer Treat Rev"},{"key":"404_CR7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10067-019-04767-z","volume":"39","author":"N Muralidharan","year":"2020","unstructured":"Muralidharan N, Sundaram R, Kodidela S, Chengappa KG, Mariaselvam CM, Misra DP, et al. Folyl polyglutamate synthetase (FPGS) gene polymorphisms may influence methotrexate adverse events in South Indian Tamil Rheumatoid Arthritis patients. Clin Rheumatol. 2020;39:471\u20139.","journal-title":"Clin Rheumatol"},{"key":"404_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2217\/pgs.15.150","volume":"17","author":"P Moya","year":"2016","unstructured":"Moya P, Salazar J, Arranz MJ, D\u00edaz-Torn\u00e9 C, Del R\u00edo E, Casademont J, et al. Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients. Pharmacogenomics. 2016;17:25\u20139.","journal-title":"Pharmacogenomics"},{"key":"404_CR9","doi-asserted-by":"crossref","unstructured":"Giletti A, Lorenzelli F, Menafra MP, Rivero F, Lorenzo M, Esper\u00f3n P. Influence of FPGS rs1544105 and GGH rs3758149 gene polymorphisms on methotrexate pharmacogenetics. Biochem Genet. 2026;64:1051\u201363.","DOI":"10.1007\/s10528-025-11058-7"},{"key":"404_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2217\/14622416.8.2.141","volume":"8","author":"RJ van der Straaten","year":"2007","unstructured":"van der Straaten RJ, Wessels JA, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Allaart CF, Bogaartz J, et al. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics. 2007;8:141\u201350.","journal-title":"Pharmacogenomics"},{"key":"404_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s43556-025-00353-9","volume":"6","author":"W Yu","year":"2025","unstructured":"Yu W, Li C, Meng Y, Li Q, Gao M, Tang W, et al. A single non-coding SNP in FPGS modulates folate drug efficacy in acute lymphoblastic leukemia: data-driven exploration and experimental validation. Molecular Biomedicine. 2025;6:114.","journal-title":"Molecular Biomedicine"},{"key":"404_CR12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2217\/pgs-2016-0191","volume":"18","author":"YH Lee","year":"2017","unstructured":"Lee YH, Bae SC. Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis. Pharmacogenomics. 2017;18:197\u2013210.","journal-title":"Pharmacogenomics"},{"key":"404_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/FPC.0b013e328331b53e","volume":"19","author":"S Sharma","year":"2009","unstructured":"Sharma S, Das M, Kumar A, Marwaha V, Shankar S, Singh P, et al. Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians. Pharmacogenet Genomics. 2009;19:823\u20138.","journal-title":"Pharmacogenet Genomics"},{"key":"404_CR14","first-page":"324","volume":"32","author":"LA Davis","year":"2014","unstructured":"Davis LA, Polk B, Mann A, Wolff RK, Kerr GS, Reimold AM, et al. Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis. Clin Exp Rheumatol. 2014;32:324.","journal-title":"Clin Exp Rheumatol"},{"key":"404_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.reuma.2016.08.006","volume":"13","author":"L Sala-Icardo","year":"2017","unstructured":"Sala-Icardo L, Lamana A, Ortiz AM, Lorenzo EG, Fresneda PM, Garc\u00eda-Vicuna R, et al. Impacto de variantes gen\u00e9ticas del transportador de membrana que une ATP B1, la aicar transformilasa\/IMP ciclohidrolasa, la folilpoliglutamatosintetasa y la metilen-tetrahidrofolatorreductasa en la toxicidad de metotrexato. Reumatolog\u00eda Cl\u00ednica. 2017;13:318\u201325.","journal-title":"Reumatolog\u00eda Cl\u00ednica"},{"key":"404_CR16","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s10067-018-4206-z","volume":"37","author":"A Sandhu","year":"2018","unstructured":"Sandhu A, Ahmad S, Kaur J, Bhatnagar A, Dhawan V, Dhir V. Do SNPs in folate pharmacokinetic pathway alter levels of intracellular methotrexate polyglutamates and affect response? A prospective study in Indian patients. Clin Rheumatol. 2018;37:3221\u20138.","journal-title":"Clin Rheumatol"},{"key":"404_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41397-019-0097-x","volume":"20","author":"N Muralidharan","year":"2020","unstructured":"Muralidharan N, Sundaram R, Kodidela S, Chengappa K, Mariaselvam CM, Misra DP, et al. Folyl polyglutamate synthethase (FPGS) gene polymorphisms may influence methotrexate adverse events in South Indian Tamil Rheumatoid Arthritis patients. Pharmacogenomics J. 2020;20:342\u20139.","journal-title":"Pharmacogenomics J"},{"key":"404_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10067-019-04770-4","volume":"39","author":"A Sandhu","year":"2020","unstructured":"Sandhu A, Dhir V, Ahmad S, Dhawan V, Kaur J, Bhatnagar A. Clinico-genetic model to predict methotrexate intolerance in rheumatoid arthritis. Clin Rheumatol. 2020;39:201\u20136.","journal-title":"Clin Rheumatol"},{"key":"404_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/srep35615","volume":"6","author":"T Yamamoto","year":"2016","unstructured":"Yamamoto T, Shikano K, Nanki T, Kawai S. Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis. Sci Rep. 2016;6:35615.","journal-title":"Sci Rep"},{"key":"404_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-016-0047-6","volume":"2","author":"M Hashiguchi","year":"2016","unstructured":"Hashiguchi M, Tsuru T, Miyawaki K, Suzaki M, Hakamata J, Shimizu M, et al. Preliminary study for predicting better methotrexate efficacy in Japanese patients with rheumatoid arthritis. J Pharm Health Care Sci. 2016;2:13.","journal-title":"J Pharm Health Care Sci"},{"key":"404_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4078\/jrd.2024.0095","volume":"32","author":"YH Lee","year":"2025","unstructured":"Lee YH, Song GG. Associations between circulating interleukin-18 levels and adult-onset Still\u2019s disease: a meta-analysis. J Rheum Dis. 2025;32:48\u201356.","journal-title":"J Rheum Dis"},{"key":"404_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4078\/jrd.2024.0149","volume":"32","author":"M Shahdadian","year":"2025","unstructured":"Shahdadian M, Saghiri MA, Capitle E. Efficacy of early rituximab treatment in primary Sj\u00f6gren's syndrome: a systematic review and meta-analysis. J Rheum Dis. 2025;32:211\u201324.","journal-title":"J Rheum Dis"},{"key":"404_CR23","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"404_CR24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"404_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"404_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta\u2010analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"404_CR27","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1002\/art.22032","volume":"54","author":"JAM Wessels","year":"2006","unstructured":"Wessels JAM, Kooloos WM, De Jonge R. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2006;54:2830\u20139.","journal-title":"Arthritis Rheum"},{"key":"404_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/tpj.2012.7","volume":"13","author":"SA Owen","year":"2013","unstructured":"Owen SA, Hider SL, Martin P, Bruce IN, Barton A, Thomson W. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J. 2013;13:227\u201334.","journal-title":"Pharmacogenomics J"},{"key":"404_CR29","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1172\/JCI112088","volume":"76","author":"BA Chabner","year":"1985","unstructured":"Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985;76:907\u201312.","journal-title":"J Clin Invest"},{"key":"404_CR30","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/17512433.2024.2416674","volume":"17","author":"Z Yang","year":"2024","unstructured":"Yang Z, Mo J, Li W, Zhao Z, Mei S. Methotrexate polyglutamates. Expert Review of Clinical Pharmacology. 2024;17:1025\u201337.","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"404_CR31","first-page":"1548","volume":"41","author":"LA Davis","year":"2014","unstructured":"Davis LA, Polk B, Mann A, Wolff RK, Kerr GS, Reimold AM, et al. Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis. J Rheumatol. 2014;41:1548\u201354.","journal-title":"J Rheumatol"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00404-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00404-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00404-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:18:41Z","timestamp":1776824321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00404-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["404"],"URL":"https:\/\/doi.org\/10.1038\/s41397-026-00404-6","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"An ethics statement is not applicable because this study is based exclusively on published literature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"11"}}